236 related articles for article (PubMed ID: 7855002)
1. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
Cher ML; Chew K; Rosenau W; Carroll PR
Prostate; 1995 Feb; 26(2):87-93. PubMed ID: 7855002
[TBL] [Abstract][Full Text] [Related]
2. Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression.
Carroll PR; Waldman FM; Rosenau W; Cohen MB; Vapnek JM; Fong P; Narayan P; Mayall BH
J Urol; 1993 Feb; 149(2):403-7. PubMed ID: 8093910
[TBL] [Abstract][Full Text] [Related]
3. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
4. Cell proliferation in colorectal adenocarcinomas: comparison between Ki-67 immunostaining and bromodeoxyuridine uptake detected by immunohistochemistry and flow cytometry.
Le Pessot F; Michel P; Paresy M; Lemoine F; Hellot MF; Paillot B; Scotte M; Peillon C; Hemet J
Pathol Res Pract; 2001; 197(6):411-8. PubMed ID: 11432668
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models.
van Weerden WM; Moerings EP; van Kreuningen A; de Jong FH; van Steenbrugge GJ; Schröder FH
Cell Prolif; 1993 Jan; 26(1):67-75. PubMed ID: 8439590
[TBL] [Abstract][Full Text] [Related]
6. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer.
Sulik M; Guzińska-Ustymowicz K
Rocz Akad Med Bialymst; 2002; 47():262-9. PubMed ID: 12533969
[TBL] [Abstract][Full Text] [Related]
7. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value.
Bantis A; Giannopoulos A; Gonidi M; Liossi A; Aggelonidou E; Petrakakou E; Athanassiades P; Athanassiadou P
Cytopathology; 2004 Feb; 15(1):25-31. PubMed ID: 14748788
[TBL] [Abstract][Full Text] [Related]
8. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
[TBL] [Abstract][Full Text] [Related]
9. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of proliferative cells.
Mokrý J; Nĕmecek S
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
[TBL] [Abstract][Full Text] [Related]
12. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder.
Cohen MB; Waldman FM; Carroll PR; Kerschmann R; Chew K; Mayall BH
Hum Pathol; 1993 Jul; 24(7):772-8. PubMed ID: 8100555
[TBL] [Abstract][Full Text] [Related]
13. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa.
Bromley M; Rew D; Becciolini A; Balzi M; Chadwick C; Hewitt D; Li YQ; Potten CS
Eur J Histochem; 1996; 40(2):89-100. PubMed ID: 8839702
[TBL] [Abstract][Full Text] [Related]
14. Comparison of proliferating cell nuclear antigen versus the more standard measures of rectal mucosal proliferation rates in subjects with a history of colorectal cancer and normal age-matched controls.
Einspahr J; Alberts D; Xie T; Ritchie J; Earnest D; Hixson L; Powell M; Roe D; Grogan T
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):359-66. PubMed ID: 7655331
[TBL] [Abstract][Full Text] [Related]
15. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract.
Lee CS
Cancer; 1996 Nov; 78(9):1881-7. PubMed ID: 8909306
[TBL] [Abstract][Full Text] [Related]
16. Comparison of proliferating cell nuclear antigen (PCNA) staining and BrdUrd-labelling index under different proliferative conditions in vitro by flow cytometry.
Lohr F; Wenz F; Haas S; Flentje M
Cell Prolif; 1995 Feb; 28(2):93-104. PubMed ID: 7893842
[TBL] [Abstract][Full Text] [Related]
17. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue.
Wijsman JH; Van Dierendonck JH; Keijzer R; van de Velde CJ; Cornelisse CJ
J Pathol; 1992 Sep; 168(1):75-83. PubMed ID: 1360499
[TBL] [Abstract][Full Text] [Related]
19. Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention.
Risio M
J Cell Biochem Suppl; 1994; 19():61-7. PubMed ID: 7823607
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA.
Hepburn PJ; Glynne-Jones E; Goddard L; Gee JM; Harper ME
Histochem J; 1995 Mar; 27(3):196-203. PubMed ID: 7797424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
